TROPION-Lung15：Dato-DXd + 奥希替尼等后奥希替尼组合试验

类型: 临床试验 / 研究监控 发表日期: 2025-12-23 入库日期: 2026-05-21 来源: ClinicalTrials.gov 标签: EGFR L858R, Datopotamab deruxtecan, 奥希替尼后, TROPION-Lung15, 临床试验

Citation

ClinicalTrials.gov search: EGFR-mutated NSCLC after osimertinib datopotamab deruxtecan TROPION-Lung15

Why it matters for mom

This is a trial-watch item rather than an established answer. It matters because post-osimertinib EGFR-mutant NSCLC is rapidly moving toward ADC combinations and biomarker-driven strategies.

Practical takeaways

• Keep TROPION-Lung15 / Dato-DXd / TROP2 ADC in the daily search agent's watchlist.
• Eligibility depends on prior therapies, measurable disease, performance status, marrow function, and geography.
• Trial availability can change quickly; check again at progression.

Questions for doctors

1. Are there open ADC trials for EGFR-mutant NSCLC after osimertinib and platinum/pemetrexed?
2. Would mom's current blood counts meet typical trial thresholds?
3. Which lesion would be measurable for RECIST if trial screening is considered?